Related Experiment Video

Updated: Feb 9, 2026

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
10:35

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

10.8K

LOXO-292 Reins In RET-Driven Tumors

    Cancer Discovery
    |June 4, 2018
    PubMed

    Insights

    LOXO-292, a potent RET inhibitor, demonstrated significant tumor shrinkage in both RET fusion-positive and RET-mutant cancers. These promising phase I findings highlight its potential in treating diverse RET-altered malignancies.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Pharmacology

    Background:

    • The study presents phase I clinical trial data for LOXO-292, a novel selective inhibitor targeting the RET proto-oncogene.
    • RET alterations, including fusions and mutations, are key drivers in various cancers, necessitating targeted therapeutic strategies.

    Discussion:

    • LOXO-292 exhibited potent activity against both RET fusion-positive and RET-mutant cancers.
    • The drug demonstrated promising anti-tumor effects, leading to measurable tumor shrinkage in patients with these specific genetic alterations.

    Key Insights:

    • Selective RET inhibition with LOXO-292 shows efficacy across different RET aberration types.
    • Phase I data indicate a favorable preliminary safety and efficacy profile for LOXO-292 in RET-driven cancers.

    Outlook:

    • Further clinical investigation is warranted to confirm these findings in larger patient cohorts.
    • LOXO-292 represents a potential new therapeutic option for patients with RET-altered cancers, pending further development.

    More Related Videos

    Light-driven Enzymatic Decarboxylation09:58

    Light-driven Enzymatic Decarboxylation

    Published on: May 22, 2016

    12.3K
    Lateral Molar Approach-Driven Transoral Endoscopic Procedure for Benign Infratemporal Fossa Tumor Resection04:04

    Lateral Molar Approach-Driven Transoral Endoscopic Procedure for Benign Infratemporal Fossa Tumor Resection

    Published on: August 15, 2025

    502

    Related Concept Videos

    ATP Driven Pumps I: An Overview01:27

    ATP Driven Pumps I: An Overview

    ATP-driven pumps, also known as transport ATPases, are integral membrane proteins. They have binding sites for ATP located on the membrane's cytosolic side and the ion-conducting domain in the transmembrane region. These pumps use the free energy released from ATP hydrolysis to move the solutes across cell membranes against an electrochemical gradient.
    There are four main types of ATP-driven pumps - P-type, V-type, F-type, and ABC transporter. All these pumps are of varying complexities and...
    9.9K
    Xylem and Transpiration-driven Transport of Resources02:03

    Xylem and Transpiration-driven Transport of Resources

    The xylem of vascular plants distributes water and dissolved minerals that are taken up by the roots to the rest of the plant. The cells that transport xylem sap are dead upon maturity, and the movement of xylem sap is a passive process.
    26.9K
    ATP Driven Pumps II: P-type Pumps01:34

    ATP Driven Pumps II: P-type Pumps

    The P-type pumps are a large family of integral membrane transporter ATPases. They are divided into five major types based on substrate specificity, from I to V.
    A typical P-type pump has three cytosolic domains: nucleotide-binding (N), phosphorylation (P), and activator (A) domains. These domains are connected to the membrane-spanning helices by short amino acid segments. ATP hydrolysis and covalent phosphoenzyme intermediate formation are crucial parts of the catalytic cycle. At the highly...
    6.5K
    ATP Driven Pumps III: V-type Pumps01:30

    ATP Driven Pumps III: V-type Pumps

    V-type pumps are ATP-driven pumps found in the vacuolar membranes of plants, yeast, endosomal and lysosomal membranes of animal cells, plasma membranes of a few specialized eukaryotic cells, and some prokaryotes. They are also known as the V1Vo-ATPase, that couple ATP hydrolysis to transport protons against a concentration gradient.
    The peripheral or cytosolic V1 domain with eight subunits is involved in ATP hydrolysis. The integral or transmembrane V0 domain containing at least five subunits...
    4.9K
    Tumor Immunotherapy01:27

    Tumor Immunotherapy

    Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
    2.0K
    Tumor Progression02:07

    Tumor Progression

    Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
    Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
    7.5K